{"ticker": {"uuid": "4c20995b-9004-419f-bdc1-2921e6e00b7d", "symbol": "CDXS", "name": "Codexis Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Codexis, Inc. \u2013 NASDAQ:CDXS", "summary": "This article provides the \"Price to earnings forward\" metric for Codexis, Inc. (NASDAQ:CDXS). It is a brief financial data point for the company, accessible through TradingView. The content primarily focuses on the display of this specific financial metric.", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:41:15", "published_display": "05 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Codexis, Inc. \u2013 NASDAQ:CDXS", "summary": "This article displays the \"Enterprise value to EBITDA forward\" for Codexis, Inc. (NASDAQ:CDXS) on the TradingView platform. It shows that the market is currently closed with no trades, and provides standard stock market information along with various TradingView features and lega", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:09:22", "published_display": "28 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results", "summary": "This article analyzes Codexis, Inc.'s recent earnings report and its impact on analyst price targets. Following the results, analysts have provided updated valuations, with the average price target now standing at US$6.58, suggesting a potential upside from the current share pric", "url": "https://news.futunn.com/en/post/72875126/us-6-58-that-s-what-analysts-think-codexis-inc", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-27T22:09:23", "published_display": "27 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Codexis, Inc. \u2013 NASDAQ:CDXS", "summary": "This page displays the forward Price to Sales ratio for Codexis, Inc. (NASDAQ: CDXS). It provides financial data for the company within the Process Industries / Chemicals: Specialty sector, indicating that the market was closed at the time of access with no trades recorded.", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:40:34", "published_display": "27 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis, Inc. Actuals & Estimates (NASDAQ:CDXS)", "summary": "This article provides a detailed overview of Codexis, Inc. (NASDAQ:CDXS) stock performance, financial actuals, and analyst estimates. It highlights key financial metrics, stock price dynamics, future forecasts, and answers frequently asked questions regarding the company's market", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:41:58", "published_display": "25 Jun 2026 19:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CDXS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Codexis, Inc. (CDXS) stock, including its current price, analyst forecasts, and key financial metrics. It highlights recent stock performance, revenue, earnings, and market capitalization, along with upcoming earnings dates. The article conclu", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:23", "published_display": "25 Jun 2026 14:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Codexis Inc (CDXS) has a financial score of 8.64, ranking 37th in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. The company reported a significant year-over-year revenue increase of 102.15% to $15.25M, with net pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T06:41:59", "published_display": "23 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis shareholders elect directors and approve proposals at annual meeting", "summary": "Codexis, Inc. (NASDAQ:CDXS) held its 2026 Annual Meeting of Stockholders where shareholders elected Stephen G. Dilly, Raymond De Vr\u00e8, and Rahul Singhvi to the board of directors for three-year terms. The meeting also saw the ratification of KPMG LLP as the company's independent r", "url": "https://m.investing.com/news/sec-filings/codexis-shareholders-elect-directors-and-approve-proposals-at-annual-meeting-93CH-4752037?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-22T10:10:48", "published_display": "22 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) shareholders back board nominees, KPMG and pay plan", "summary": "Codexis, Inc. shareholders voted at the 2026 Annual Meeting to re-elect Stephen G. Dilly, Raymond De Vr\u00e9, and Rahul Singhvi to the board for three-year terms. They also ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, ", "url": "https://www.stocktitan.net/sec-filings/CDXS/8-k-codexis-inc-reports-material-event-7974674a2832.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:10:48", "published_display": "22 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Codexis Inc For: 22 June By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 8K by Codexis Inc. on June 22. It lists various stock market indices, commodities, and individual stocks with their current prices and daily changes. The article also highlights popular news related to tech companies ", "url": "https://ca.investing.com/news/stock-market-news/form-8k-codexis-inc-for-22-june-93CH-4700186", "source_name": "Investing.com Canada", "published_at": "2026-06-22T10:10:48", "published_display": "22 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director receives option grant for 66,350 shares", "summary": "Codexis (CDXS) director Esther Martinborough received a stock option grant for 66,350 shares at an exercise price of $2.48 per share. These options vest upon the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on her continued", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-4b5f17bef7d0.html", "source_name": "Stock Titan", "published_at": "2026-06-19T17:10:51", "published_display": "19 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (NASDAQ: CDXS) director receives 66,350 options vesting in one year", "summary": "Codexis (NASDAQ: CDXS) director Rahul Singhvi was granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. The options vest fully on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, conditiona", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-968aa7686257.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:13", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director David V. Smith granted 66,350 stock options at $2.48", "summary": "Codexis (CDXS) director David V. Smith was granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. This grant serves as equity compensation and is not an open-market trade. The options will vest on the earlier of the first anniversary of", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-9f78972302b0.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:01", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Codexis (CDXS) receives 66,350 stock options grant", "summary": "Codexis (CDXS) director Cynthia Collins was granted 66,350 stock options with an exercise price of $2.48 per share. These options vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting and expire in 2036. This transaction is a form o", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-62d69a7cb179.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:01", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CODEXIS (CDXS) director receives 66,350 stock options at $2.48 strike price", "summary": "CODEXIS director Christos Richards was granted 66,350 stock options with an exercise price of $2.48 per share. These options, awarded at no cost, will vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided Richards ", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-c4bb72dbc9ba.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:01", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director Parker H. Stewart receives 66,350 stock options", "summary": "Codexis (CDXS) director Parker H. Stewart has been granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. The options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-1d0204aa9875.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:01", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director Raymond De Vre awarded 66,350 stock options at $2.48", "summary": "Codexis (CDXS) director Raymond De Vre was granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. The options will vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-1d60acde8e5e.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:09:13", "published_display": "18 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) grants director 66,350 stock options at $2.48", "summary": "Codexis (CDXS) director Stephen George Dilly was granted 66,350 stock options at an exercise price of $2.48 per share, as part of his compensation package. These options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, pr", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-bab3c556ab56.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:09:13", "published_display": "18 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "The article details the shareholder structure of Codexis Inc (CDXS), listing its major shareholders and their proportions, including abrdn Inc., Opaleye Management Inc., and BlackRock Institutional Trust Company, N.A. It also categorize shareholders by type, such as investment ad", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:47:01", "published_display": "18 Jun 2026 09:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Institutional Confidence", "summary": "Codexis Inc (CDXS) has an institutional shareholding score of 7.00, placing it 81st out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 73.00%, a 13.55% decrease quarter-over-quarter. Bill Nygren, holding 332.07K shares, is th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:29", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Codexis Inc (CDXS) has an earnings forecast score of 8.00, ranking 163 out of 388 in its industry. Analysts have set an average price target of $7.00, with a consensus \"Buy\" rating based on 7 analysts. The company's expected revenue for the next quarter is $14.35 million, and its", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:28", "published_display": "18 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Codexis Inc (CDXS), detailing its financial performance by region. As of April 6, the company's total revenue was $70.49 million, with America contributing the largest share at 61.85%. Data for business segments and profit contributio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:44", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CDXS: All proposals, including director elections and auditor ratification, were approved without contest", "summary": "During the Codexis, Inc. (CDXS) 2026 AGM, all proposals, including director elections and auditor ratification, were approved without contest. A quorum was confirmed, and no stockholder questions were raised. The voting results for these approved proposals will be officially repo", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3609960:0-cdxs-all-proposals-including-director-elections-and-auditor-ratification-were-approved-without-contest/", "source_name": "TradingView", "published_at": "2026-06-17T17:10:44", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Codexis stock rating on oligo platform", "summary": "Cantor Fitzgerald reaffirmed an Overweight rating and an $11.00 price target for Codexis, Inc., citing the significant potential of oligonucleotide therapeutics and Codexis' enzymatic ECO Synthesis Manufacturing Platform. The firm highlighted that the platform is well-positioned ", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-codexis-stock-rating-on-oligo-platform-93CH-4747119", "source_name": "Investing.com", "published_at": "2026-06-17T16:39:28", "published_display": "17 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis director Raymond de Vre sells $6,173 in shares", "summary": "Codexis director Raymond De Vre sold 2,605 shares of the company's common stock for $6,173 to cover tax liabilities from Restricted Stock Units. Following the sale, Mr. De Vre directly holds 84,811 shares. This transaction occurs after Codexis shares surged 44% in six months and ", "url": "https://m.uk.investing.com/news/insider-trading-news/codexis-director-raymond-de-vre-sells-6173-in-shares-93CH-4725019?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-12T02:09:30", "published_display": "12 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director De Vre sells 2,605 shares to cover RSU tax liability", "summary": "Codexis director Raymond De Vre sold 2,605 shares of common stock for $2.37 per share on June 11, 2026. This sale was primarily to cover tax liabilities associated with vested Restricted Stock Units (RSUs) and is considered a mechanical transaction rather than a discretionary inv", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-beb2a76f0d9a.html", "source_name": "Stock Titan", "published_at": "2026-06-12T00:40:25", "published_display": "12 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA", "summary": "Codexis highlighted new advancements in RNA therapeutic manufacturing at TIDES USA 2026, focusing on its ECO Synthesis Manufacturing Platform. The company demonstrated full-length siRNA synthesis with precise stereochemical control and introduced the ability to initiate enzymatic", "url": "https://ca.finance.yahoo.com/news/codexis-highlights-stereochemistry-advances-scalable-130000860.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-05-21T04:40:03", "published_display": "21 May 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNQTV0cUFmWTlqcndJUzRsREZSaUpqZm5JU2E4MVUyT3BNekhyMC1nb0ZKQjdtdTg0SDNkSG8xZkVrTmEtR182NDFyRnpHajFZdjRYaHVfZ2NOZmFGU2g3ak9kdTVfNkRsTlRTS01SLTliMzhsOU02dTJXSk1rWVZSX3RMU3hXZG1kUzJNVlRsaU0teE9oQmticE81cUxFVEVTU3c?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Codexis (CDXS) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/1d859212-2bbb-3bfa-a855-878ec6ef8b84/codexis-%28cdxs%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T19:32:42+00:00", "published_display": "08 May 2026 19:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/dd6fc2e0-6fd7-3936-9840-a90f693b1089/codexis%2C-inc.-q1-2026.html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/0694a861-5279-3dc6-a0f1-fb2f687f3dab/codexis-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-07T21:39:36+00:00", "published_display": "07 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/codexis-q1-earnings-snapshot-213404111.html", "source_name": "Associated Press", "published_at": "2026-05-07T21:34:04+00:00", "published_display": "07 May 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNWk92NTJMbnJIeDNOSU1iYWt4SlpSSU9SMHBDQnVvaWhha0JDa1hVT083ZFRqQUY3ZVlYQTgxUTlqRWU1akJFSm13TXhVY1FibjJkSnF2MndVd2JuZmZfNUE2dnVPTHEzSDNwcnRSdnlvWFFjNDM2VWJ2Skxlamx2b3JYa2VJVlUyOHNMcFZHUkJ0WmVEQUhHZA?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNbkNJdHRVYW5qOHQ5Vm5ITmg3NFE1d2k4WDRpNVFDcDZFRndfeU5UeEZnX0x1TmJzVTRDQWV4V2RlTEo0TklNSnFoQjhsbjRUa2Q4Wi1GS0UwV3pDWXJNUWpiNnJEM19mMF92RlJhLV9VZlV6TWZtOFJGbkt3NWhFZU1MeFY3cEYwR0xGbWtiaUk3RFhtRW9SMmJodWNNM1I3cVllNWJseUU2Rk0xX19xa1ZpNFBhWTVvUUcyekJyWjZuR0lTMVlB?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis says it has cash through 2027 as siRNA plans advance", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQSWVVY1Q3WGlnVVFudTdYNG1fMS1qUU5FN3RNdUFVR2s0dTVOeEZOdXpudFVSU0QtckloWVRnd2hhWU1zejlMSEUxcHlQX0NpSXRNcS1NWEoxM3d5WHRWNVE0ZWdjMXpJcTNhZ2Myd1dtTzczTEsxZGJBZS1aRmxLY2xYenNjdkU2aThldTExRUt0M2RjS0tpcU04RnM2cEJM?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPTXpQY0VQelIxQk5yaV9zZG9uM0gxalhNU3Ywa3R6VFhObE5WS013cjdkM2F6YkppTDhvZnktLXN1cGRTM20tMFJ6WnRTNThvazlLMHM5d2c0LThzM1kwTDFMV1lhazJDRWR4UVIyam1zeTYxaEdoYlByNVJBdnZhYnZWRE16dFpRMWFMRENORFVzZldJZXlqSjBrT3JZR2pmT2c?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Codexis sets May 7 earnings call, business update at 4:30 p.m. ET", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOME43TFh4R0hyQ0M5M2VIN1J1ZEY5UW4yNlREQ0lSeDY3dDRIdGFEQmtMbDRaVi1tS2NkWElXSVdqUHBZdE82UjQyUEU2Z1kxUy1KNWRiYzVlTjhoaUdPYUlmT1ZMcS1SbHZCR2IxUV9xZ29aaXEtLTM1ZHpmLUdXTGNCb0xjVnRtaTJaNl9oVHNxV0lCUTREaUJmdkRYRlJPaUNfbXRhQmY1TERsWjRucnZTbG5aVUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analyst Sentiment Unchanged After Codexis (CDXS) Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSjlWdWFfMjlpUS0tbHpnOUFvbW5LVFMtTWRSMjExdi1ZaU9BVXo5c3VMMXViZFpWNmZMU3JLaXVYbXE1SVJEMjZsQ2NmNlUzeEhRenhLX2J2UHFnNHZTb2VYWjMzRm41Q0ZmUml3UjJSdjlOUjBrdlVXMGxCZlNEcnBaRmRuV0tKR2J0dzJfZzZNTllBZzFCTU5KMFZPSkx4LVR5SDU2dVo?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue Guidance - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Codexis (CDXS) Valuation After Strong Earnings And New ECO Synthesis siRNA Agreement", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Is Up 30.9% After Returning To Q4 Profitability And Issuing 2026 Revenue Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE93NUtES1U5U3Z5QlZ5MUY5WWp6STJ3OVo2U1EwSGwwLVgtWjZLek9GaVcxRk1NOWpnR3YtV3paU1UwLWlSdkY1SnpkTUJ3NktoNzA5OUp4OGRzVVVhUTlTQzlVTVRYOFQ1Zld1eUhsRi13ODExa2tSOWpiWWp2dw?oc=5", "source_name": "Market source", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Q4 Profit Turns Positive EPS Into Test Of Turnaround Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis stock rises after Q4 beat, outlook (CDXS:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE53RlR2eUVOTmNkQmNLUDJOSFF1SVZkREdxd3FLMkpnMVFLZ2Z2dkRWbkxGR01rQ1dPTzJyb2ZnTnhrbmpiNUtEZ0tLOWI2RWUzVF9PaE90RzV6Ulg2YXVIYXRRd05YczRyeG53MHMxWlFKMGpkR1hhQk5wTVdEZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform (NASDAQ:CDXS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPWkgzM1RFOWtGc3ZhdENWSGRXOC1VeHFadU44ZDZ2SzV5WExjbm1LdGx5MjdpOWkyRldXWW10STZPc2tkQmh6dlA5T1BZMzBMZHgtZ05mVU8yNURrTWZpQm4xQ3pna3lxampaU0dIWVk2eVZnY2VpZXI4VVVYY3IyUS01MG5NN1gyaTU1dUxDNTNjRFV5UnQ4N3BPbDg4LWVvelpxNXZCY0N5TXgyNEVn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Sentiment Still Eludes Codexis, Inc. (NASDAQ:CDXS) Following 29% Share Price Slump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Codexis, Inc. (NASDAQ:CDXS) Before Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVlFnSFpiblN3RzgxbEl3TUVRRnNFSTNMSktnSC0yckVqSm9qSTNPUDREckF3SjRRRlB0a1BNRE5ta0FJUGt2RVFnblFvXzFKNElIZ2ROTWtsVmxPZThKa2hzTmtLOWVwbG1xTXVGMG5ndzJVNlBHbEsyRGV1Sk4yYWFpNVJYWkl6RnFz?oc=5", "source_name": "Market source", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (NASDAQ:CDXS investor five-year losses grow to 84% as the stock sheds US$29m this past week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-01T07:00:00+00:00", "published_display": "01 Nov 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of Codexis, Inc. \u2013 NASDAQ:CDXS", "summary": "This article provides the \"Price to earnings forward\" metric for Codexis, Inc. (NASDAQ:CDXS). It is a brief financial data point for the company, accessible through TradingView. The content primarily focuses on the display of this specific financial metric.", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T00:41:15", "published_display": "05 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Codexis, Inc. \u2013 NASDAQ:CDXS", "summary": "This article displays the \"Enterprise value to EBITDA forward\" for Codexis, Inc. (NASDAQ:CDXS) on the TradingView platform. It shows that the market is currently closed with no trades, and provides standard stock market information along with various TradingView features and lega", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:09:22", "published_display": "28 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results", "summary": "This article analyzes Codexis, Inc.'s recent earnings report and its impact on analyst price targets. Following the results, analysts have provided updated valuations, with the average price target now standing at US$6.58, suggesting a potential upside from the current share pric", "url": "https://news.futunn.com/en/post/72875126/us-6-58-that-s-what-analysts-think-codexis-inc", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-27T22:09:23", "published_display": "27 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Codexis, Inc. \u2013 NASDAQ:CDXS", "summary": "This page displays the forward Price to Sales ratio for Codexis, Inc. (NASDAQ: CDXS). It provides financial data for the company within the Process Industries / Chemicals: Specialty sector, indicating that the market was closed at the time of access with no trades recorded.", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:40:34", "published_display": "27 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis, Inc. Actuals & Estimates (NASDAQ:CDXS)", "summary": "This article provides a detailed overview of Codexis, Inc. (NASDAQ:CDXS) stock performance, financial actuals, and analyst estimates. It highlights key financial metrics, stock price dynamics, future forecasts, and answers frequently asked questions regarding the company's market", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:41:58", "published_display": "25 Jun 2026 19:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CDXS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Codexis, Inc. (CDXS) stock, including its current price, analyst forecasts, and key financial metrics. It highlights recent stock performance, revenue, earnings, and market capitalization, along with upcoming earnings dates. The article conclu", "url": "https://www.tradingview.com/symbols/NASDAQ-CDXS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:23", "published_display": "25 Jun 2026 14:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Codexis Inc (CDXS) has a financial score of 8.64, ranking 37th in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. The company reported a significant year-over-year revenue increase of 102.15% to $15.25M, with net pr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T06:41:59", "published_display": "23 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis shareholders elect directors and approve proposals at annual meeting", "summary": "Codexis, Inc. (NASDAQ:CDXS) held its 2026 Annual Meeting of Stockholders where shareholders elected Stephen G. Dilly, Raymond De Vr\u00e8, and Rahul Singhvi to the board of directors for three-year terms. The meeting also saw the ratification of KPMG LLP as the company's independent r", "url": "https://m.investing.com/news/sec-filings/codexis-shareholders-elect-directors-and-approve-proposals-at-annual-meeting-93CH-4752037?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-22T10:10:48", "published_display": "22 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) shareholders back board nominees, KPMG and pay plan", "summary": "Codexis, Inc. shareholders voted at the 2026 Annual Meeting to re-elect Stephen G. Dilly, Raymond De Vr\u00e9, and Rahul Singhvi to the board for three-year terms. They also ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, ", "url": "https://www.stocktitan.net/sec-filings/CDXS/8-k-codexis-inc-reports-material-event-7974674a2832.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:10:48", "published_display": "22 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Codexis Inc For: 22 June By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 8K by Codexis Inc. on June 22. It lists various stock market indices, commodities, and individual stocks with their current prices and daily changes. The article also highlights popular news related to tech companies ", "url": "https://ca.investing.com/news/stock-market-news/form-8k-codexis-inc-for-22-june-93CH-4700186", "source_name": "Investing.com Canada", "published_at": "2026-06-22T10:10:48", "published_display": "22 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director receives option grant for 66,350 shares", "summary": "Codexis (CDXS) director Esther Martinborough received a stock option grant for 66,350 shares at an exercise price of $2.48 per share. These options vest upon the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on her continued", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-4b5f17bef7d0.html", "source_name": "Stock Titan", "published_at": "2026-06-19T17:10:51", "published_display": "19 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (NASDAQ: CDXS) director receives 66,350 options vesting in one year", "summary": "Codexis (NASDAQ: CDXS) director Rahul Singhvi was granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. The options vest fully on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, conditiona", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-968aa7686257.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:09:13", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director David V. Smith granted 66,350 stock options at $2.48", "summary": "Codexis (CDXS) director David V. Smith was granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. This grant serves as equity compensation and is not an open-market trade. The options will vest on the earlier of the first anniversary of", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-9f78972302b0.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:01", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Codexis (CDXS) receives 66,350 stock options grant", "summary": "Codexis (CDXS) director Cynthia Collins was granted 66,350 stock options with an exercise price of $2.48 per share. These options vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting and expire in 2036. This transaction is a form o", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-62d69a7cb179.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:01", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CODEXIS (CDXS) director receives 66,350 stock options at $2.48 strike price", "summary": "CODEXIS director Christos Richards was granted 66,350 stock options with an exercise price of $2.48 per share. These options, awarded at no cost, will vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided Richards ", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-c4bb72dbc9ba.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:01", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director Parker H. Stewart receives 66,350 stock options", "summary": "Codexis (CDXS) director Parker H. Stewart has been granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. The options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-1d0204aa9875.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:47:01", "published_display": "18 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director Raymond De Vre awarded 66,350 stock options at $2.48", "summary": "Codexis (CDXS) director Raymond De Vre was granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. The options will vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-1d60acde8e5e.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:09:13", "published_display": "18 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) grants director 66,350 stock options at $2.48", "summary": "Codexis (CDXS) director Stephen George Dilly was granted 66,350 stock options at an exercise price of $2.48 per share, as part of his compensation package. These options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, pr", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-bab3c556ab56.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:09:13", "published_display": "18 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "The article details the shareholder structure of Codexis Inc (CDXS), listing its major shareholders and their proportions, including abrdn Inc., Opaleye Management Inc., and BlackRock Institutional Trust Company, N.A. It also categorize shareholders by type, such as investment ad", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:47:01", "published_display": "18 Jun 2026 09:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Institutional Confidence", "summary": "Codexis Inc (CDXS) has an institutional shareholding score of 7.00, placing it 81st out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 73.00%, a 13.55% decrease quarter-over-quarter. Bill Nygren, holding 332.07K shares, is th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:29", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Codexis Inc (CDXS) has an earnings forecast score of 8.00, ranking 163 out of 388 in its industry. Analysts have set an average price target of $7.00, with a consensus \"Buy\" rating based on 7 analysts. The company's expected revenue for the next quarter is $14.35 million, and its", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:28", "published_display": "18 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Inc (CDXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Codexis Inc (CDXS), detailing its financial performance by region. As of April 6, the company's total revenue was $70.49 million, with America contributing the largest share at 61.85%. Data for business segments and profit contributio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cdxs/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:44", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CDXS: All proposals, including director elections and auditor ratification, were approved without contest", "summary": "During the Codexis, Inc. (CDXS) 2026 AGM, all proposals, including director elections and auditor ratification, were approved without contest. A quorum was confirmed, and no stockholder questions were raised. The voting results for these approved proposals will be officially repo", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3609960:0-cdxs-all-proposals-including-director-elections-and-auditor-ratification-were-approved-without-contest/", "source_name": "TradingView", "published_at": "2026-06-17T17:10:44", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Codexis stock rating on oligo platform", "summary": "Cantor Fitzgerald reaffirmed an Overweight rating and an $11.00 price target for Codexis, Inc., citing the significant potential of oligonucleotide therapeutics and Codexis' enzymatic ECO Synthesis Manufacturing Platform. The firm highlighted that the platform is well-positioned ", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-codexis-stock-rating-on-oligo-platform-93CH-4747119", "source_name": "Investing.com", "published_at": "2026-06-17T16:39:28", "published_display": "17 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis director Raymond de Vre sells $6,173 in shares", "summary": "Codexis director Raymond De Vre sold 2,605 shares of the company's common stock for $6,173 to cover tax liabilities from Restricted Stock Units. Following the sale, Mr. De Vre directly holds 84,811 shares. This transaction occurs after Codexis shares surged 44% in six months and ", "url": "https://m.uk.investing.com/news/insider-trading-news/codexis-director-raymond-de-vre-sells-6173-in-shares-93CH-4725019?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-12T02:09:30", "published_display": "12 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) director De Vre sells 2,605 shares to cover RSU tax liability", "summary": "Codexis director Raymond De Vre sold 2,605 shares of common stock for $2.37 per share on June 11, 2026. This sale was primarily to cover tax liabilities associated with vested Restricted Stock Units (RSUs) and is considered a mechanical transaction rather than a discretionary inv", "url": "https://www.stocktitan.net/sec-filings/CDXS/form-4-codexis-inc-insider-trading-activity-beb2a76f0d9a.html", "source_name": "Stock Titan", "published_at": "2026-06-12T00:40:25", "published_display": "12 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA", "summary": "Codexis highlighted new advancements in RNA therapeutic manufacturing at TIDES USA 2026, focusing on its ECO Synthesis Manufacturing Platform. The company demonstrated full-length siRNA synthesis with precise stereochemical control and introduced the ability to initiate enzymatic", "url": "https://ca.finance.yahoo.com/news/codexis-highlights-stereochemistry-advances-scalable-130000860.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-05-21T04:40:03", "published_display": "21 May 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNQTV0cUFmWTlqcndJUzRsREZSaUpqZm5JU2E4MVUyT3BNekhyMC1nb0ZKQjdtdTg0SDNkSG8xZkVrTmEtR182NDFyRnpHajFZdjRYaHVfZ2NOZmFGU2g3ak9kdTVfNkRsTlRTS01SLTliMzhsOU02dTJXSk1rWVZSX3RMU3hXZG1kUzJNVlRsaU0teE9oQmticE81cUxFVEVTU3c?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/1d859212-2bbb-3bfa-a855-878ec6ef8b84/codexis-%28cdxs%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-08T19:32:42+00:00", "published_display": "08 May 2026 19:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/dd6fc2e0-6fd7-3936-9840-a90f693b1089/codexis%2C-inc.-q1-2026.html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/0694a861-5279-3dc6-a0f1-fb2f687f3dab/codexis-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-07T21:39:36+00:00", "published_display": "07 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/codexis-q1-earnings-snapshot-213404111.html", "source_name": "Associated Press", "published_at": "2026-05-07T21:34:04+00:00", "published_display": "07 May 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNWk92NTJMbnJIeDNOSU1iYWt4SlpSSU9SMHBDQnVvaWhha0JDa1hVT083ZFRqQUY3ZVlYQTgxUTlqRWU1akJFSm13TXhVY1FibjJkSnF2MndVd2JuZmZfNUE2dnVPTHEzSDNwcnRSdnlvWFFjNDM2VWJ2Skxlamx2b3JYa2VJVlUyOHNMcFZHUkJ0WmVEQUhHZA?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNbkNJdHRVYW5qOHQ5Vm5ITmg3NFE1d2k4WDRpNVFDcDZFRndfeU5UeEZnX0x1TmJzVTRDQWV4V2RlTEo0TklNSnFoQjhsbjRUa2Q4Wi1GS0UwV3pDWXJNUWpiNnJEM19mMF92RlJhLV9VZlV6TWZtOFJGbkt3NWhFZU1MeFY3cEYwR0xGbWtiaUk3RFhtRW9SMmJodWNNM1I3cVllNWJseUU2Rk0xX19xa1ZpNFBhWTVvUUcyekJyWjZuR0lTMVlB?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis says it has cash through 2027 as siRNA plans advance", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQSWVVY1Q3WGlnVVFudTdYNG1fMS1qUU5FN3RNdUFVR2s0dTVOeEZOdXpudFVSU0QtckloWVRnd2hhWU1zejlMSEUxcHlQX0NpSXRNcS1NWEoxM3d5WHRWNVE0ZWdjMXpJcTNhZ2Myd1dtTzczTEsxZGJBZS1aRmxLY2xYenNjdkU2aThldTExRUt0M2RjS0tpcU04RnM2cEJM?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPTXpQY0VQelIxQk5yaV9zZG9uM0gxalhNU3Ywa3R6VFhObE5WS013cjdkM2F6YkppTDhvZnktLXN1cGRTM20tMFJ6WnRTNThvazlLMHM5d2c0LThzM1kwTDFMV1lhazJDRWR4UVIyam1zeTYxaEdoYlByNVJBdnZhYnZWRE16dFpRMWFMRENORFVzZldJZXlqSjBrT3JZR2pmT2c?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis sets May 7 earnings call, business update at 4:30 p.m. ET", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOME43TFh4R0hyQ0M5M2VIN1J1ZEY5UW4yNlREQ0lSeDY3dDRIdGFEQmtMbDRaVi1tS2NkWElXSVdqUHBZdE82UjQyUEU2Z1kxUy1KNWRiYzVlTjhoaUdPYUlmT1ZMcS1SbHZCR2IxUV9xZ29aaXEtLTM1ZHpmLUdXTGNCb0xjVnRtaTJaNl9oVHNxV0lCUTREaUJmdkRYRlJPaUNfbXRhQmY1TERsWjRucnZTbG5aVUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Sentiment Unchanged After Codexis (CDXS) Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSjlWdWFfMjlpUS0tbHpnOUFvbW5LVFMtTWRSMjExdi1ZaU9BVXo5c3VMMXViZFpWNmZMU3JLaXVYbXE1SVJEMjZsQ2NmNlUzeEhRenhLX2J2UHFnNHZTb2VYWjMzRm41Q0ZmUml3UjJSdjlOUjBrdlVXMGxCZlNEcnBaRmRuV0tKR2J0dzJfZzZNTllBZzFCTU5KMFZPSkx4LVR5SDU2dVo?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue Guidance - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Codexis (CDXS) Valuation After Strong Earnings And New ECO Synthesis siRNA Agreement", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Is Up 30.9% After Returning To Q4 Profitability And Issuing 2026 Revenue Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE93NUtES1U5U3Z5QlZ5MUY5WWp6STJ3OVo2U1EwSGwwLVgtWjZLek9GaVcxRk1NOWpnR3YtV3paU1UwLWlSdkY1SnpkTUJ3NktoNzA5OUp4OGRzVVVhUTlTQzlVTVRYOFQ1Zld1eUhsRi13ODExa2tSOWpiWWp2dw?oc=5", "source_name": "Market source", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (CDXS) Q4 Profit Turns Positive EPS Into Test Of Turnaround Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis stock rises after Q4 beat, outlook (CDXS:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE53RlR2eUVOTmNkQmNLUDJOSFF1SVZkREdxd3FLMkpnMVFLZ2Z2dkRWbkxGR01rQ1dPTzJyb2ZnTnhrbmpiNUtEZ0tLOWI2RWUzVF9PaE90RzV6Ulg2YXVIYXRRd05YczRyeG53MHMxWlFKMGpkR1hhQk5wTVdEZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform (NASDAQ:CDXS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPWkgzM1RFOWtGc3ZhdENWSGRXOC1VeHFadU44ZDZ2SzV5WExjbm1LdGx5MjdpOWkyRldXWW10STZPc2tkQmh6dlA5T1BZMzBMZHgtZ05mVU8yNURrTWZpQm4xQ3pna3lxampaU0dIWVk2eVZnY2VpZXI4VVVYY3IyUS01MG5NN1gyaTU1dUxDNTNjRFV5UnQ4N3BPbDg4LWVvelpxNXZCY0N5TXgyNEVn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Sentiment Still Eludes Codexis, Inc. (NASDAQ:CDXS) Following 29% Share Price Slump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Codexis, Inc. (NASDAQ:CDXS) Before Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVlFnSFpiblN3RzgxbEl3TUVRRnNFSTNMSktnSC0yckVqSm9qSTNPUDREckF3SjRRRlB0a1BNRE5ta0FJUGt2RVFnblFvXzFKNElIZ2ROTWtsVmxPZThKa2hzTmtLOWVwbG1xTXVGMG5ndzJVNlBHbEsyRGV1Sk4yYWFpNVJYWkl6RnFz?oc=5", "source_name": "Market source", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Codexis (NASDAQ:CDXS investor five-year losses grow to 84% as the stock sheds US$29m this past week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-01T07:00:00+00:00", "published_display": "01 Nov 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 55, "sentiment_summary": {"positive": 12, "negative": 5, "neutral": 38, "score": 53, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 78, "events": [{"event": "earnings", "label": "Earnings", "weight": 15.2, "count": 29}, {"event": "general", "label": "Market update", "weight": 12.45, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.9, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 2.43, "latest_week": "2026-07-10", "one_week_move": -1.6, "four_week_move": 1.3, "twelve_week_move": -6.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.069408, "market_dynamics_buy_signal": false, "relative_strength": -3.141823, "fair_value_gap": -11.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.0652, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.6% over one week, +1.3% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 11}, {"label": "TradingView", "count": 7}, {"label": "simplywall.st", "count": 7}, {"label": "TradingKey", "count": 5}, {"label": "Investing.com", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "\u5bcc\u9014\u725b\u725b", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 29}, {"label": "Market update", "count": 22}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.6% over one week, +1.3% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of Codexis, Inc. \u2013 NASDAQ:CDXS"}], "updated_at": "2026-07-15T23:35:00.670936+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}